# A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure

> **NCT01641367** · PHASE4 · COMPLETED · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 545 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Darunavir
- **DRUG:** Etravirine
- **DRUG:** Emtricitabine/tenofovir disoproxil fumarate
- **DRUG:** Raltegravir
- **DRUG:** Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)
- **DRUG:** Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available
- **OTHER:** SOC adherence versus SOC+CPI adherence

## Key facts

- **NCT ID:** NCT01641367
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-22
- **Primary completion:** 2016-11-23
- **Final completion:** 2018-12-31
- **Target enrollment:** 545 (ACTUAL)
- **Last updated:** 2019-03-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01641367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01641367, "A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01641367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*